SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Carrus Capital Corporation Announces Final Court Order for Plan of Arrangement, Share Distribution Record Date, and Share Consolidation

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/11/14 -- Carrus Capital Corporation (the "Company" or "Carrus") (TSX VENTURE: CHQ) is pleased to announce that on March 26, 2014, the Company obtained a final order from the Supreme Court of British Columbia to the implementation of the plan of arrangement.

The Company is also pleased to announce that it will be implementing the approved spin-off of BioAB Strategies Ltd. ("BioAB"), BioDE Ventures Ltd. ("BioDE"), and BioHEP Technologies Ltd. ("BioHEP") to Carrus shareholders of record on April 11, 2014 (the "Share Distribution Record Date"). No action is required by Carrus shareholders in order to receive shares of BioAB, BioDE, and BioHEP. Shareholders entitled to receive shares of BioAB, BioDE, and BioHEP will receive a DRS advice reflecting their ownership, or their brokerage account will be credited with the shares. A bulletin has been issued today from the TSX Venture Exchange with respect to the distribution. The payable date is the same as the Share Distribution Record Date of April 11, 2014.

Pursuant to the Arrangement, shareholders of Carrus will receive 1 BioAB share, 1 BioDE share and 1 BioHEP share (collectively referred to as the "Distributed Shares") for every 5 Carrus Shares they hold as of the Share Distribution Record Date of April 11, 2014.

The redemption price of the Carrus Class A Preferred Shares per share is equal to $5,000/2,845,381 shares and the paid up capital of these Carrus Class A Preferred Shares per share is equal to $5,000/2,845,381 shares. Therefore, every 5 shares of the Carrus Preferred Shares redeemed will result in a distribution of 1 BioAB Share, 1 BioDE Share and 1 BioHEP Share to each shareholder. Thus, the adjusted cost base for the Distributed Shares for each of the subsidiaries will be equal to the total fair value of assets transferred, divided by the total number of Distributed Shares (ie: $5,000/2,845,381 shares). As a result, shareholders receiving the BioAB Shares, BioDE Shares and BioHEP Shares should not experience any capital gain on redemption of the Carrus Class A Preferred Shares. However, shareholders should seek their own professional advice in order to determine the amount of capital gain, if any, they may experience on redemption of the Carrus Class A Preferred Shares.

Spin-off of three wholly owned subsidiaries:


----------------------------------------------------------------------------
Carrus Capital     Transfer from    Transfer from        Total fair value of
Corporation        Carrus: Cash     Carrus:              transferred assets
(14,226,904 shares                  Pharmaceutical       per subsidiary
as of record date)                  portfolio
Subsidiaries (1
share for every 5
Carrus shares held)
----------------------------------------------------------------------------
BioAB              $5,000.00        MX-2401 antibiotic   $5,000.00
(2,845,381                          assets and
Distributed Shares)                 contracts ($Nil
                                    value)
----------------------------------------------------------------------------
BioDE              $5,000.00        Omiganan-based       $5,000.00
(2,845,381                          technologies with
Distributed Shares)                 anti-infective
                                    properties, related
                                    contracts, and
                                    CLS001 ($Nil value)
----------------------------------------------------------------------------
BioHEP             $5,000.00        SB-9000, Springbank  $6,000.00
(2,845,381                          shares, hepatitis
Distributed Shares)                 assets and
                                    contracts ($1,000
                                    value)
----------------------------------------------------------------------------
Aggregate Fair Market Value (Total)
(Aggregate Paid-up Capital - 14,226,904 Carrus Preferred $16,000.00
Shares)
----------------------------------------------------------------------------

In addition, the Company intends to consolidate its share capital concurrently with the spin-off, and expects to receive director approval to consolidate its share capital on the basis of one (1) new common share for every seven (7) currently issued and outstanding common shares. Registered shareholders of the Company will receive the letter of transmittal containing instructions on how to obtain new share certificates of Carrus by mail. The letter of transmittal will be posted on SEDAR under the Company's profile at www.sedar.com. The share consolidation is subject to final acceptance from the TSX Venture Exchange.

The securities referred to in this news release have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This news release does not constitute an offer for sale of securities for sale, nor a solicitation for offers to buy any securities. Any public offering of securities in the United States must be made by means of a prospectus containing detailed information about the company and management, as well as financial statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contacts:
Carrus Capital Corporation
Bruce Schmidt
Chief Executive Officer, Corporate Secretary & Director
604-760-0160

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.